BioSpace News Archive

The $13.8 million facility that will include training sites, biotech wet laboratories, clean rooms, and office and event spaces is now looking for organizations and companies to fill the space.

MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.

Major framework agreement signed with Life Healthcare Distribution (“LHC”) for the exclusive distribution of HEMOBLAST Bellows in the sizeable and growing Australian market

Somerset, NJ-based CRO Catalent announced it is acquiring Baltimore-based Paragon BioServices for $1.2 billion.

Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).

Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.

For decades, independently owned pharmacies have maintained a reputation for locally rooted, personalized service.

International law firm McDermott Will & Emery has launched its new Compliance Toolkit and Checkup program for Physician Practice Management (PPM) organizations.

Ian Jenkins, CEO of Frelii Inc. (OTCQB: FRLI) (“Frelii” or “The Company”) met in an informal meeting with Canadian Prime Minister, Justin Trudeau to discuss how Frelii’s artificial intelligence (AI) technology could be beneficial in advancing the safe and more effective use of medical cannabis products in Canada.

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its Annual Report for 2018 is now available on the company’s website, www.alzecurepharma.se.